Analysis of metal complex with synchrotron spectroscopy
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB |
| Funding from Vinnova | SEK 748 000 |
| Project duration | November 2023 - April 2025 |
| Status | Completed |
| Venture | Research infrastructure - utilisation and collaboration |
| Call | Development project for increased industrial utilization of neutron and synchrotron light-based technologies, 2023 |
Important results from the project
The project focused on elucidating the structure of a new organometallic compound being developed by the company Renapharma for the treatment of nutrient deficiencies. In collaboration with RISE, robust synthesis methods were developed, and crystals were obtained for 3D structure determination. However, the 3D structure could not be resolved due to crystal twinning. Despite this, a reference material was generated that can be used in future commercial manufacturing.
Expected long term effects
A robust synthesis method was developed to produce different solid forms of the drug candidate using various solvents and counterions. Crystals were analyzed with DSC, XRPD, LM, and elemental analysis to confirm their composition. For 3D structure determination, single-crystal X-ray diffraction was performed at the European Synchrotron Radiation Facility (ESRF) in Grenoble. Despite using different crystals and extensive data processing, crystal twinning prevented structure determination.
Approach and implementation
Robust synthetic method for the synthesis of different solid forms of the candidate drug was developed, using different solvents and counter ions. The crystals were analysed with DSC, XRPD LM and elemental analysis to confirm the content. Crystals were then analyzed at a synchrotron by single crystal X-ray diffraction to elucidate the 3D-structure. Despite using different solid samples and extended data handling crystal twinning prohibited the elucidation of structure.